WEBINAR: Proof of concept to phase 2 clinical development: Inhaled Oxytocin, a case study.

Description

Delve into the innovative journey of developing a new medicine using the Inhaled Oxytocin project as a case study. This technology was devised and initially developed at Monash University and is now entering clinical development in collaboration with GSK and philanthropic funding partners. 

Our guest speaker, Associate Professor Pete Lambert, from the Department of Pharmacy and Pharmaceutical Sciences at Monash University, brings over 20 years of expertise in pharmaceutical product development.

KEY TOPICS:

- Development pathway for new medicines

- Proof of concept

- Phase 2 clinical development

- Running not-for-profit programs

- Partnering with pharmaceuticals

SPEAKER:

Pete Lambert, Pharmacy and Pharmaceutical Sciences, Monash University

ABOUT PETE LAMBERT:

Peter is a pharmaceutical scientist and programme director specialising in global health R&D. He currently leads the inhaled oxytocin project seeking to develop a novel oxytocin product to better manage postpartum haemorrhage in low resource settings.

He is also a co-coordinator of the Global Health Therapeutic Program Area at Monash Institute of Pharmaceutical Sciences.

Originally trained as a pharmacist, Pete has 20+ years experience in product development in the pharmaceutical industry.